A 12-Week, Multinational, Randomised, Double Blind, Double Dummy, 4-Arm Parallel-Group Study Comparing the Efficacy and Safety of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 microg/Actuation Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 microg/Actuation, Via HFA Pressurised Inhalation Solution, in Moderate to Severe Symptomatic Asthmatic Patients Aged greater than or equal to 12 Years Under Treatment With Inhaled Corticosteroids.

Trial Profile

A 12-Week, Multinational, Randomised, Double Blind, Double Dummy, 4-Arm Parallel-Group Study Comparing the Efficacy and Safety of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 microg/Actuation Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 microg/Actuation, Via HFA Pressurised Inhalation Solution, in Moderate to Severe Symptomatic Asthmatic Patients Aged greater than or equal to 12 Years Under Treatment With Inhaled Corticosteroids.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 May 2014

At a glance

  • Drugs Beclometasone/formoterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 24 Mar 2012 Additional trial location added as reported by European Clinical Trials Database.
    • 24 Mar 2012 This trial in 'recruiting' in Hungary.
    • 22 Dec 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top